San Francisco startup Construction Therapeutics is also working on an oral, at the time-daily GLP-1 drug called GSBR-1290—the drug surpassed Wall Street’s expectations in June any time a mid-stage research confirmed ordinary weight loss of all over 6% and it plans to start another mi